DIGITAL CONTENT INCLUDED: VIDEO LECTURES ONLY
Multiple Sclerosis Care
Is Entering a New Era.
The 2026 Mellen Center Update in Multiple
Sclerosis brings together clinically focused education addressing
major developments in multiple sclerosis and related neuroimmunologic disorders.
The program translates recent advances in MS research into practical
clinical approaches, with attention to treatment selection, disease progression,
rehabilitation, infection risk and complex neuroimmunologic disease.
BTK Inhibitors &
Progressive Multiple Sclerosis
One of the major highlights of the program examines emerging
Phase 3 evidence surrounding Bruton’s tyrosine kinase inhibitors
and their potential implications for progressive multiple sclerosis.
BTK Inhibitors in Multiple Sclerosis
Integrating Phase 3 Trial Evidence to Address Progressive Disease
What Is Changing in MS Care?
Disease-Modifying Therapies
Treatment selection, monitoring and infection-risk considerations.
Progressive Multiple Sclerosis
Early recognition, monitoring and emerging therapeutic strategies.
NMOSD & Autoimmune Encephalitis
Treatment selection, antibody testing and therapeutic sequencing.
Rehabilitation & Disability
Fatigue, cognition, mobility, spasticity and long-term rehabilitation.
Artificial Intelligence
The expanding role of AI in diagnosis, clinical decisions and patient outcomes.
Control Disease.
Manage Treatment Risk.
Modern MS treatment requires clinicians to balance disease control with
the risks associated with long-term immunomodulatory therapy.
Complex Neuroimmunologic Disorders
AQP4+ Neuromyelitis Optica Spectrum Disorder
Practical considerations surrounding first-line therapy and
new FDA-approved monoclonal antibodies.
Autoimmune Encephalitis
A practical approach to diagnosis, antibody testing
and treatment sequencing.
Treatment Is More Than
Disease Modification.
The program places substantial emphasis on long-term function,
mobility, fatigue and interdisciplinary rehabilitation.
Different Patients.
Different Clinical Challenges.
Clinical insights from puberty through menopause.
DMT transition, psychosocial care and rehabilitation.
Engagement, coping and quality-of-life support.
Strategies to reduce loss to follow-up and improve continuity of care.
Artificial Intelligence
in Multiple Sclerosis
The course examines the expanding role of artificial intelligence
and its potential impact on diagnosis, treatment, clinical decision-making
and patient outcomes.
Integrating AI-Driven Insights in Multiple Sclerosis
After Completing the Course
16 Video Lectures
Complete 2026 Mellen Center Multiple Sclerosis & Neuroimmunology video curriculum.
Choosing First-Line Therapy in AQP4+ NMOSD
Kaitlyn Palmer • Justin R. Abbatemarco • 25:49
Men with MS: Engagement, Coping & Quality-of-Life Support
Amy Sullivan • 07:11
Older-Adult MS: Psychosocial Care, DMT Transition & Rehabilitation
Grace Tworek • 08:19
Multiple Sclerosis and Social Determinants
Brianne Markley • 06:29
Multiple Sclerosis Vaccination Strategies
Brent Sokola • 19:46
Integrating AI-Driven Insights in Multiple Sclerosis
Moein Amin • 20:54
MS DMTs: Infection Risk Profiles & Prevention Strategies
Robert Fox • 26:47
MS Case Studies: Managing Infection Risk with DMTs
Hilary Young • Jennifer Basalla • Shauna Gales • Jennifer Sedlak • 29:11
MS Progression: Early Recognition & Monitoring
Devon Conway • Amjad Samara • 28:39
MS Hormone Modulation: Puberty to Menopause
Alise Carlson • Katherine Havard-Coiro • 23:18
BTK Inhibitors in Multiple Sclerosis
Jiwon Oh • 47:22
MS Rehabilitation Strategies
Francois Bethoux • 34:37
Autoimmune Encephalitis: Diagnosis, Antibody Testing & Treatment Sequencing
Amy Kunchok • 34:09
MS Cognitive Fatigue: Evidence-Based Pacing
Danielle Brown • 30:12
MS Wheelchair Evaluation: Proactive Five-Year Coverage Planning
Alyssa Decarlo • 33:59
MS Symptom Triad: Fatigue, Heat Intolerance & Spasticity
Danielle Brown • Alyssa Decarlo • Kellie Keim • Kaitlin Sparks • 34:34
Who Is This Course For?
From Disease Modification
to Whole-Patient MS Care
Recognize Progression.
Navigate New Therapies.
Advance MS Care.
A focused 2026 clinical update covering disease-modifying therapies,
BTK inhibitors, progressive MS, NMOSD, autoimmune encephalitis,
rehabilitation, symptom management and artificial intelligence.
Reviews
There are no reviews yet.